Usage And Safety
Side Effects
Diziness , headache , fatigue , emotional lability , abdominal pain / distension , musculoskeletal pain, early or rarely delayed menstruation. soreness , diarrhoea , flatulence with rectal route.
Drug Interactions
CYP450-3A4 such as barbiturates, anti-epileptic agents (phenytoin, carbamazepine), rifampicin, phenylbutazone, bromcriptine, spironolactone, griseofulvin, some antibiotics (ampicillins, tetracyclines) and also herbal products containing St. John's wort, (Hypericum perforatum) , Ketokonazole and other inhibitors of CYP450-3A4 such as ritonavir and nelfinavir , ciclosporin , Aminoglutethimide , coumarins , anti-diabetic drugs , diazepam , tizanidine , terbinafine .
Indication
It is used in various female reproductive health conditions associated with low progesterone.
When not to Use
Known hypersensitivity to the active substances, soybean lecithin, peanut or to any of the excipients listed . Known or Past or suspected breast cancer , Known or suspected estrogen-dependent malignant tumours (e.g genital tract carcinoma) , Undiagnosed genital bleeding.
Warnings
Warning 1
For the treatment of postmenopausal symptoms, HRT should only be initiated for symptoms that adversely affect quality of life. In all cases, a careful appraisal of the risks and benefits should be undertaken at least annually, and HRT should only be continued as long as the benefit outweighs the risk.
Warning 2
HRT is associated with a 1.3-3 fold risk of developing venous thromboembolism (VTE), i.e. deep vein thrombosis or pulmonary embolism.
Warning 3
Women already on chronic anticoagulant treatment require careful consideration of the benefit-risk of use of HRT.
